The company, on an update conference call, says it didn’t disclose the limb girdle patient death on the Wednesday update call as it “wasn’t salient to our discussions on Wednesday.” Sarepta (SRPT) says “this doesn’t change in any way” either the safety signal for Elevitus or the approach the company is taking. As it relates to the Wednesday event, “it simply was neither material nor relevant,” Sarepta added. Shares of Sarepta are down 17% in morning trading to $18.25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Another liver toxicity death adds to Sarepta concerns, says Morgan Stanley
- Sarepta price target lowered to $20 from $28 at BofA
- Sarepta not disclosing death ‘deeply troubling,’ says Leerink
- Sarepta knew of patient death when announcing restructuring , Stat says
- Sarepta patient death could bring greater scrutiny, says William Blair